Custom Thymosin β4 acetate (TB500) CAS: 77591-33-4 Manufacturers, Pricelist

This is the most in-depth and fastest-progressing area of research. Tβ4 promotes repair through multiple mechanisms:

• Promotes the migration of keratinocytes and endothelial cells: accelerates skin epithelialization and granulation tissue formation.
• Stimulates angiogenesis: brings oxygen and nutrients to repaired tissues.
• Anti-inflammatory effect: Reduces inflammatory cell infiltration and improves the repair microenvironment.
• Reduce fibrosis: Reduce scar formation by regulating collagen production.

• Skin ulcers: such as diabetic foot ulcers, pressure sores, varicose ulcers, etc. Related drugs (such as RGN-137) have already completed clinical trials.
• Corneal injury: Promotes corneal epithelial regeneration and is used for chemical burns, erosions, and xerosis. Related eye drop formulations have entered clinical trials.
• Oral mucositis: Commonly seen as a side effect of chemotherapy and radiotherapy; Tβ4 can accelerate its healing.

This is another very promising area. Following a myocardial infarction (heart attack), Tβ4 has been shown to:

• Promotes cardiomyocyte survival: reduces cell apoptosis.
• Stimulates angiogenesis: Improves blood flow to the infarcted area.
• Recruiting stem cells: Mobilizing endogenous cardiac stem cells or progenitor cells to promote myocardial tissue regeneration (although this mechanism is somewhat controversial).
• Improves cardiac function: Reduces scar formation and improves cardiac output.

Primarily used for cardiac repair after acute myocardial infarction and for the treatment of chronic heart failure. Some early clinical trials (such as the REGEN trial) have shown its safety and potential benefits, but subsequent larger-scale studies have yielded mixed results and require further validation.

Based on its neurotrophic and neuroprotective properties, Tβ4 also shows potential in neurological diseases:

• Stroke: In ischemic stroke models, Tβ4 can reduce infarct size, promote neurogenesis and angiogenesis, and improve motor function recovery.
• Multiple sclerosis: In an experimental autoimmune encephalomyelitis model, Tβ4 exhibits anti-inflammatory and myelin regeneration-promoting effects.
• Traumatic brain injury and spinal cord injury: Protects neurological function through anti-inflammatory, anti-apoptotic and neuroplasticity-promoting effects.

• Hair regeneration: Research has found that Tβ4 can activate hair follicle stem cells, promoting the hair growth cycle to transition from the resting phase to the anagen phase. Some companies have already attempted to develop it into hair regrowth products.
• Anti-aging: Due to its ability to promote tissue regeneration and maintain stem cell function, Tβ4 is considered by some studies as a potential "regenerative medicine" molecule to combat age-related tissue function decline.
• Liver and lung fibrosis: Due to its anti-fibrotic properties, it is being investigated for the treatment of cirrhosis and pulmonary fibrosis.

• The mechanism of action is clear and multi-effect: Tβ4 works through multiple pathways, which means that it can synergistically promote repair at multiple levels and may be more effective than single-target drugs.
• Natural endogenous substances: As proteins produced by the human body itself, they have low immunogenicity and are theoretically safe.

• Ophthalmic applications appear to be one of the areas closest to commercialization. Several Tβ4-based ophthalmic drugs have shown promising efficacy and safety in treating corneal damage.
• Some products used in dermatology have also entered late-stage clinical trials.
• A star molecule in regenerative medicine: With the rise of regenerative medicine and anti-aging research, Tβ4, as a key molecule that can activate stem cells and promote tissue regeneration, continues to attract the attention of the scientific community and biotechnology companies.

• Inconsistent clinical outcomes: Especially in the field of cardiac repair, early positive results have not been consistently replicated in large-scale clinical trials, and more data are needed to support the significance and stability of the efficacy.
• The challenge of drug delivery: As peptides, oral administration leads to degradation, typically requiring local injection or topical application. Efficiently delivering the drug to target tissues such as the heart and brain is a significant technical challenge.
• Commercialization and Regulatory Pathways: Developing a novel regenerative therapy with a complex mechanism of action requires substantial financial investment and faces stringent regulatory approval processes. Some projects may be halted due to insufficient funding or failure to meet clinical trial endpoints.
• A deeper understanding of the mechanism of action: Although we know that Tβ4 has many functions, its precise molecular targets and signaling pathway networks are not yet fully elucidated, which limits targeted drug optimization.